US-based developer of accessible blood-based liquid biopsy tests that deliver a new way to enhance early cancer detection DELFI Diagnostics, Inc. announced on Monday that it has named Thomas Russo as its new chief financial officer (CFO).

Most recently, Russo has served as CFO of Icosavax, Inc and Assembly Biosciences, and senior finance and commercial operations roles at Gilead Sciences. He has worked as Equity Research Senior Analyst covering biotechnology for Robert W Baird & Co. Inc. He has also served in roles of increasing responsibility within Merck & Co's manufacturing division.

Susan Tousi, DELFI Diagnostics CEO, said, 'Tom has a proven track record of supporting innovators in healthcare, and his combined expertise across biopharma, finance, commercialisation, and the investment community makes him an incredible addition to our growing team of industry visionaries. DELFI is poised to revolutionise cancer screening to better support providers and patients. Tom's appointment expands our capabilities to ensure fiscal excellence, drive adoption at scale, and fulfil the company's potential.'